TAFI – Thrombin Activatable Fibrinolysis Inhibitor Polyclonal Antibody
Affinity’s TAFI – Thrombin Activatable Fibrinolysis Inhibitor Polyclonal Antibody is the base level of our TAFI – Thrombin Activatable Fibrinolysis Inhibitor antibody family. The purity of IgG is typically 90% and is provided in a solution of HEPES buffered saline containing 50% glycerol (v/v). The titre is essentially the same as the starting antiserum and each vial typically contains the amount of IgG recovered from one milliliter of antiserum. This TAFI – Thrombin Activatable Fibrinolysis Inhibitor Polyclonal Antibody is generally intended for use in applications such as immuno-precipitation, immuno-electrophoresis, immuno-depletion and activity neutralization assays.
Product Code: SATAFI-IG
Retail Product Size: 10mg vial
Host Animal: Sheep Anti-Human TAFI – Thrombin Activatable Fibrinolysis Inhibitor Polyclonal Antibody
Species Cross Reactivity: View Chart
Description of Thrombin Activatible Fibrinolysis Inhibitor (TAFI)
TAFI (Thrombin Activatable Fibrinolysis Inhibitor), also referred to as plasma procarboxypeptidase-B, procarboxypeptidase-U and R, circulates in plasma as a zymogen with a mass of 58,000 daltons (1-6). Proteolytic activation of TAFI yields an N-terminally derived activation peptide and the C-terminal portion corresponding to the metalloprotease, activated TAFI (TAFIa). TAFIa exhibits exopeptidase activity with carboxypeptidase B-like substrate specificity capable of catalyzing the hydrolysis of C-terminal lysine and arginine residues. Cleavage of these residues on fibrin by TAFIa attenuates clot lysis by inhibiting the formation of the ternary activation complex comprising fibrin cofactor, tPA and plasminogen, thereby inhibiting plasmin generation. Although TAFI can be activated by various proteases including thrombin and plasmin, the physiological activator is proposed to be the complex thrombin-thrombomodulin since the rate of activation is stimulated 1250-fold compared to thrombin alone (4). However, the rate of TAFI activation is highly dependent upon its plasma concentration. Since TAFIa apparently plays a key role in connecting coagulation and fibrinolysis and significantly increases clot stability, determination of plasma concentration of TAFI is likely crucial to assess its subsequent potential antifibrinolytic effects1-6.
References and Reviews
- Eaton, D.L., Malloy, B.E., Tsai, S.P., Henzel, W., Drayna, D., Isolation, Molecular Cloning and Partial Characterization of a Novel Carboxypeptidase B from Human Plasma. J.Biol.Chem. 266:21833-21838, 1991.
- Hendriks, D., Scharpe, S., van Sande, M., Lommaert, M.P., Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase N. J.Clin.Chem.Clin.BioChem. 27:277-285, 1989.
- Campbell, W., Okada, J. An Arginine specific carboxypeptidase generated in blood during coagulation of inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem.Biophys.Res.Commun. 162:933-939, 1989.
- Bajzar, L., Morser, J., Nesheim, M.E. TAFI, or procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J.Biol.Chem. 271:16603-16608, 1996.
- Mosnier, L.O., von Dem Borne, P.A. Meijers, J.C., Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb.Haemost. 80:829-835, 1998.
- Juhan-Vague, I., Renucci, J.F., and Grimaux, M., Morange, P.E., Gouvernet, J., Gourmelin, Y., Laessi, M.C. Thrombin Activatable Fibrinolysis Inhibitor Antigen Levels and cardiovascular Risk Factors. Arter.Thromb.Vascular.Biology. 20:2156-2161, 2000.